Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) …
T Seto, T Kato, M Nishio, K Goto, S Atagi… - The lancet …, 2014 - thelancet.com
Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) …
T Seto, T Kato, M Nishio, K Goto, S Atagi, Y Hosomi… - The Lancet …, 2014 - Elsevier
Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) …
T Seto, T Kato, M Nishio, K Goto… - The Lancet …, 2014 - kyushu-u.elsevierpure.com
Background: With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) …
T Seto, T Kato, M Nishio, K Goto, S Atagi… - The Lancet …, 2014 - europepmc.org
Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) …
T Seto, T Kato, M Nishio, K Goto, S Atagi, Y Hosomi… - The Lancet …, 2014 - infona.pl
With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR
mutation-positive non-small-cell lung cancer (NSCLC), median progression-free survival …
mutation-positive non-small-cell lung cancer (NSCLC), median progression-free survival …
[PDF][PDF] Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFRmutations …
T Seto, T Kato, M Nishio, K Goto, S Atagi, Y Hosomi… - Lancet Oncol, 2014 - Citeseer
Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutationpositive non-small-cell lung cancer (NSCLC), median progression …
activating EGFR mutationpositive non-small-cell lung cancer (NSCLC), median progression …
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFRmutations (JO25567) …
T Seto, T Kato, M Nishio, K Goto, S Atagi, Y Hosomi… - Lancet Oncol, 2014 - thelancet.com
Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutationpositive non-small-cell lung cancer (NSCLC), median progression …
activating EGFR mutationpositive non-small-cell lung cancer (NSCLC), median progression …
[PDF][PDF] Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFRmutations …
T Seto, T Kato, M Nishio, K Goto, S Atagi… - Lancet …, 2014 - cloudfront.practiceupdate.net
Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutationpositive non-small-cell lung cancer (NSCLC), median progression …
activating EGFR mutationpositive non-small-cell lung cancer (NSCLC), median progression …
[引用][C] Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations …
T Seto, T Kato, M Nishio, K Goto, S Atagi… - The Lancet …, 2014 - cir.nii.ac.jp
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous
non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised …
non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised …
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) …
T Seto, T Kato, M Nishio, K Goto… - The Lancet …, 2014 - pubmed.ncbi.nlm.nih.gov
Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …